Italian company the Menarini Group has agreed to pay Chinese insulin maker Gan & Lee Pharmaceuticals €62 million ($72 million) up front to collaborate on the registration and commercialization of Gan & Lee’s GLP-1 bofanglutide. Gan & Lee will also be eligible to receive milestone payments of up to €664 million ($771 million), as well as double-digit royalties on sales, according to a release . Menarini will take over regulatory submissions and commercialization in a total of 39 countries, incl

Pfizer has found a new home for an early-stage antibody-drug conjugate (ADC) it gained through its $43-billion takeout of Seagen — then subsequently binned — according to a US securities filing from Medicus Pharma on Wednesday. In March, the pharma terminated a Phase I trial of PF-08046031 (SGN-CD228A) in patients with melanoma and other solid tumours, citing "strategic reasons." The melanotransferrin (CD228)–targeting candidate is one of more than a half-dozen Seagen-sourced ADCs that Pfizer h

GSK is spending up to $1.3 billion on a first-of-its-kind cancer therapy slated to enter the clinic this year. In a deal announced Thursday, GSK agreed to pay Hutchmed $110 million up front, and potentially roughly $1.19 billion more in milestone payments and royalties, for a majority of the rights to a treatment known as HMPL-A830. That treatment is what Hutchmed refers to as an “antibody-targeted therapeutic conjugate,” and could potentially address multiple tumor types. Typical antibody-dru

Partnership will support Resolution’s pivotal clinical program in 2027, as well as future commercial preparedness for RTX001, its lead asset in patients with end-stage liver disease (ESLD) Primary goal is to ensure patients can access treatment in the community setting, where the majority of decompensated patients are managed RTX001 has the potential to be the first treatment that demonstrates a clear and durable improvement in transplant free survival for ESLD patients Sept. 01, 2026 -- Reso

Roche's Genentech unit inked an agreement with DualityBio, potentially exceeding $1 billion, to develop next-generation antibody-drug conjugates (ADCs) built on the latter's proprietary platform. The collaboration announced Friday aims to integrate DualityBio’s ADC payload and clinical development expertise with Roche’s oncology capabilities to target tumours that do not respond to topoisomerase inhibitor-based ADCs. DualityBio CEO John Zhu said that with topoisomerase inhibitor-based ADCs mov

Through its DualityBio deal, Roche’s Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance. Just days after announcing a deal with a South Korean company, Roche’s Genentech is now partnering with Shanghai-based DualityBio to advance next-generation antibody-drug conjugates for cancer. Under the terms of the deal, Genentech will pay $45 million upfront and set aside up to more than $1 billion in development, regulatory and commercial

Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill's commercial GI business The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a material

Teva has agreed to bid up to $125 million for BioXcel Therapeutics' neuroscience assets, including marketed agitation treatment Igalmi (dexmedetomidine), as the struggling biotech enters Chapter 11 bankruptcy. Teva will serve as the stalking-horse bidder in a court-supervised auction for substantially all of BioXcel's assets. Under the agreement, Teva would pay $57.5 million upfront for worldwide rights to the assets, with up to another $67.5 million in contingent payments. The latter includes

ProFound Therapeutics has received up to $35 million in backing from the Gates Foundation, including an initial $20 million, to use its proteomics and AI platform to identify drug targets and biomarkers for preeclampsia and eclampsia. The Flagship Pioneering-founded biotech will analyse proteins found in the placenta and serum of women with the pregnancy complications. "The expanded proteome represents a vast and largely untapped resource for identifying novel protein drugs, drug targets," said

SK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market. Biohaven is currently evaluating the daily oral therapy, called opakalim or BHV-7000, in a phase 2/3 study of patients with focal epilepsy. A topline readout is expected later this year. Rather than wait for the results, SK has agreed to hand over the upfront cash—along with another $50 million next year—for the worldwide license t